Excelsior Biopharma Inc. (TPEX:6496)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
23.85
0.00 (0.00%)
Nov 10, 2026, 1:30 PM CST

Excelsior Biopharma Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-184.7-183.17-98.71-91.01-33.76-15.65
Depreciation & Amortization
69.5771.6870.9646.2226.0628.65
Loss (Gain) From Sale of Assets
-3.730.65----
Loss (Gain) From Sale of Investments
-----0.21
Loss (Gain) on Equity Investments
-2.19-2.18-0.25---
Stock-Based Compensation
0.260.280.330.260.04-
Provision & Write-off of Bad Debts
3.8-2.562.250.98-3.674.47
Other Operating Activities
4.88-1.82.816.750.785.53
Change in Accounts Receivable
-30.34-45.81-30.53-27.1782.26-35.87
Change in Inventory
-35.1817.75-85.65-28.716.0271.88
Change in Accounts Payable
51.05-38.7842.43-16.92-49.79-18.52
Change in Other Net Operating Assets
33.4545.22-3.44-25.15-32.4615.13
Operating Cash Flow
-93.15-138.72-99.8-134.755.4955.82
Operating Cash Flow Growth
-----90.17%-89.28%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-8.29-36.95-257.15-35.66-7.78-2.88
Sale of Property, Plant & Equipment
3.762.25----
Investment in Securities
11.4511.45-55.5199.74-200-6.01
Other Investing Activities
1.28-1.155.62-17.478.54-1.8
Investing Cash Flow
8.19-24.4-307.03146.62-199.24-10.68

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-159.610.010.01--
Long-Term Debt Issued
--110---
Total Debt Issued
259.61159.61110.010.01--
Short-Term Debt Repaid
---0.01-0.01--
Long-Term Debt Repaid
--51.97-53.98-317.23-13.73-12.64
Lease Payments
-50.68-51.97-53.98-17.93-13.73-12.64
Total Debt Repaid
-110.51-51.97-53.99-317.24-13.73-12.64
Net Debt Issued (Repaid)
149.1107.6456.02-317.23-13.73-12.64
Repurchase of Common Stock
------23.74
Common Dividends Paid
------46.67
Other Financing Activities
-10.740.98---
Financing Cash Flow
148.1108.3856.99-317.23-13.73-83.04

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
63.37-54.74-349.84-305.36-207.49-37.9

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-101.44-175.67-356.95-170.41-2.352.95
Free Cash Flow Growth
------89.60%
Free Cash Flow Margin
-10.57%-19.56%-41.41%-22.09%-0.34%3.96%
Free Cash Flow Per Share
-2.19-3.81-7.74-3.71-0.051.14
Levered Free Cash Flow
-28.46-104.35-311.04-139.514.4359.32
Unlevered Free Cash Flow
-22.25-99.49-306.02-135.537.1562.16
Free Cash Flow After Leases
-152.11-227.64-410.93-188.33-16.0340.31

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
7.657.657.961.360.881.12
Cash Income Tax Paid
12.412.48.368.388.283.46
Change in Working Capital
18.97-21.62-77.19-97.9516.0332.61